Top 25 Companies in Diabetic Retinopathy Market in the World in 2025: Market Research Report (2024–2035)

Description

According to a research report published by Spherical Insights & Consulting, The Global Diabetic Retinopathy Market Size is projected To Grow from USD 6.04 Billion in 2024 to USD 28.44 Billion by 2035, at a CAGR of 16.76 % during the forecast period 2025–2035. The diabetic retinopathy market offers opportunities in AI-driven diagnostics, tele-ophthalmology, advanced imaging, novel drug therapies, and minimally invasive surgeries, fueled by rising diabetes prevalence and demand for early detection and effective treatment.

 

 

Introduction                                                             

The Diabetic Retinopathy Market Size is focused on addressing one of the most common complications of diabetes that affects the eyes and can lead to vision loss if untreated. Characterized by damage to the retina’s blood vessels due to prolonged high blood sugar levels, diabetic retinopathy is becoming a growing global health concern. The rising prevalence of diabetes, increasing geriatric population, and lifestyle changes are driving demand for advanced diagnostic tools and treatment options. Continuous innovations in imaging technologies, pharmacological therapies, and surgical procedures are shaping this market, while early detection and preventive care remain critical growth drivers worldwide.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights - Download the Brochure now and dive deeper into the future of the Diabetic Retinopathy market.

 

 Diabetic Retinopathy Market Size & Statistics

• The Market Size for Diabetic Retinopathy Was Estimated to be Worth USD 6.04 Billion in 2024.
• The Market Size is Going to Expand at a CAGR of 16.76 % Between 2025 and 2035.
• The Global Diabetic Retinopathy Market is Anticipated to Reach USD 28.44 Billion by 2035.
• North America is expected to generate the highest demand during the forecast period in the Diabetic Retinopathy Market.
• Asia Pacific is expected to grow the fastest during the forecast period in the Diabetic Retinopathy Market.

 

 

Regional growth and demand

                                    

Asia Pacific is expected to grow the fastest during the forecast period in the Diabetic Retinopathy market. This growth is driven by the rising prevalence of diabetes, increasing healthcare awareness, expanding access to advanced eye care, and government initiatives aimed at strengthening healthcare infrastructure across emerging economies like India and China.

 

North America is expected to generate the highest demand during the forecast period in the Diabetic Retinopathy market. This is largely due to the high prevalence of diabetes, advanced healthcare infrastructure, strong presence of leading pharmaceutical and medical device companies, and widespread adoption of advanced diagnostic and treatment technologies. Additionally, increasing healthcare spending, favorable reimbursement policies, and continuous R&D investments further strengthen North America’s dominant role in driving demand for diabetic retinopathy solutions.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the Diabetic Retinopathy market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Top 5 Trends in Diabetic Retinopathy Market

1. AI-Driven Diagnostics

Artificial Intelligence (AI) is transforming diabetic retinopathy detection by enabling faster, more accurate, and cost-effective screenings. AI-powered tools analyze retinal images to identify early signs of the disease with minimal human intervention. This technology enhances access to diagnosis in remote areas, where ophthalmologists may be limited. Major healthcare providers are adopting AI-based screening tools to improve efficiency and reduce misdiagnosis rates. With the rise of teleophthalmology and digital health platforms, AI-driven diagnostics are making diabetic retinopathy care more accessible and scalable, ultimately supporting early intervention and improved patient outcomes across diverse populations worldwide.

 

2. Growth of Non-Invasive Imaging

Advancements in non-invasive retinal imaging technologies, such as Optical Coherence Tomography (OCT) and fundus photography, are boosting diabetic retinopathy detection and monitoring. These technologies provide high-resolution images of retinal layers, allowing precise identification of microaneurysms, hemorrhages, and other disease markers. Portable and handheld imaging devices are gaining traction, especially in community health programs, making screening more convenient and widespread. With faster image processing and integration into electronic health records, non-invasive imaging enhances both diagnostic accuracy and patient comfort. The shift toward painless, efficient, and accurate tools is a major driver in the early detection and management of diabetic retinopathy.

 

3. Rise of Anti-VEGF Therapies

Anti-VEGF (vascular endothelial growth factor) therapies are emerging as a standard treatment for diabetic retinopathy and diabetic macular edema. These targeted therapies help reduce abnormal blood vessel growth and fluid leakage, preventing vision loss. Drugs such as ranibizumab and aflibercept are gaining wider adoption due to their efficacy in improving visual outcomes compared to conventional treatments like laser therapy. The development of longer-lasting formulations and sustained-release delivery systems is enhancing treatment compliance. As clinical trials continue to expand therapeutic applications, anti-VEGF therapies are expected to remain a key trend shaping the diabetic retinopathy market.

 

4. Teleophthalmology Expansion

Teleophthalmology is expanding rapidly, enabling remote screening, diagnosis, and monitoring of diabetic retinopathy. With rising digital health adoption, patients can now undergo retinal imaging at local clinics, with images shared electronically for specialist review. This model bridges the gap in underserved areas, particularly in rural and emerging markets, where access to ophthalmologists is limited. Coupled with AI-powered diagnostics, teleophthalmology reduces costs, improves access, and supports early disease intervention. Governments and healthcare providers are increasingly investing in these programs to curb preventable blindness, making teleophthalmology a critical driver of market growth during the forecast period.

 

5. Focus on Personalized Medicine

Personalized medicine is gaining prominence in diabetic retinopathy management, with treatments tailored to individual genetic, metabolic, and lifestyle factors. Advances in biomarkers, genetic testing, and precision therapies are enabling more targeted interventions, improving treatment efficacy and reducing side effects. For instance, predictive biomarkers are being used to identify patients at higher risk of rapid disease progression, allowing timely preventive care. Pharmaceutical companies are investing in customized therapeutic strategies and drug delivery systems, enhancing long-term patient outcomes. As research deepens into genetic and molecular mechanisms, personalized medicine will redefine the future of diabetic retinopathy treatment.

 

Top 10 Companies Leading the Diabetic Retinopathy Market

1. Bayer AG
2. Allergan plc
3. Novartis AG
4. Oxurion NV
5. Sirnaomics Inc.
6. Genentech
7. Alimera Sciences
8. Ampio Pharmaceuticals
9. BCN Peptides
10. Kowa Company, Ltd.

 

1. Bayer AG

Bayer AG, headquartered in Leverkusen, Germany, is a global leader in life sciences with a strong presence in pharmaceuticals, consumer health, and crop science. In the diabetic retinopathy market, Bayer plays a key role through its ophthalmology division, offering therapies such as Eylea® (aflibercept), an anti-VEGF drug used to treat diabetic macular edema and proliferative diabetic retinopathy. Bayer focuses on innovative R&D, strategic collaborations, and clinical trials to advance vision-saving treatments. With a strong global footprint, cutting-edge technologies, and commitment to patient-centric care, Bayer continues to drive progress in improving outcomes for diabetic retinopathy patients worldwide.

 

2. Allergan plc

Allergan plc, now part of AbbVie Inc., is a leading pharmaceutical company with expertise in eye care, central nervous system, medical aesthetics, and gastroenterology. In the diabetic retinopathy space, Allergan offers therapies such as Ozurdex® (dexamethasone intravitreal implant), which provides long-term control of diabetic macular edema. The company emphasizes innovative drug delivery systems and therapies that improve patient adherence and treatment outcomes. With strong global distribution networks and a legacy of leadership in ophthalmology, Allergan continues to play a pivotal role in advancing effective, minimally invasive treatments for diabetic retinopathy, ensuring better vision care for patients worldwide.

 

3. Novartis AG

Novartis AG, headquartered in Basel, Switzerland, is one of the world’s largest pharmaceutical companies with a strong portfolio in ophthalmology. Novartis markets Lucentis® (ranibizumab), a widely used anti-VEGF therapy for diabetic retinopathy and diabetic macular edema. The company also invests in next-generation therapies, including gene therapy and sustained-release treatments, aimed at improving long-term patient outcomes. Novartis leverages its global research network, partnerships, and robust pipeline to deliver breakthrough innovations in eye care. Its commitment to advancing precision medicine and accessibility makes it a leader in the diabetic retinopathy market, addressing unmet needs and reducing preventable blindness globally.

 

4. Oxurion NV

Oxurion NV, headquartered in Leuven, Belgium, is a biopharmaceutical company specializing in the development of innovative therapies for retinal disorders, including diabetic retinopathy and diabetic macular edema. The company’s pipeline includes THR-149 (a plasma kallikrein inhibitor) and THR-687 (an integrin antagonist), both in clinical trials for treating vision-threatening diabetic eye diseases. Oxurion focuses on novel, first-in-class therapies that provide alternatives to current anti-VEGF treatments, targeting patients who are unresponsive to existing therapies. By advancing pioneering drug candidates and strategic collaborations, Oxurion aims to transform diabetic retinopathy care and establish itself as a leader in next-generation retinal disease therapeutics.

 

5. Sirnaomics Inc.

Sirnaomics Inc., a biopharmaceutical company headquartered in Gaithersburg, Maryland, USA, specializes in RNAi-based therapeutics targeting ophthalmology, oncology, and fibrotic diseases. In the diabetic retinopathy market, Sirnaomics is developing novel small interfering RNA (siRNA) therapies designed to silence genes responsible for pathological angiogenesis and vascular leakage in the retina. These treatments hold promise for more durable and precise disease management compared to conventional therapies. With a strong pipeline of RNAi-based candidates, proprietary delivery technologies, and growing strategic partnerships, Sirnaomics is emerging as an innovative player in ophthalmology. Its focus on next-generation gene-silencing solutions positions it as a disruptor in diabetic retinopathy treatment.

 

Are you ready to discover more about the Diabetic Retinopathy market?

The report provides an in-depth analysis of the leading companies operating in the global Diabetic Retinopathy market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Company Profiles

1. Bayer AG.
   • Business Overview
   • Company Snapshot
   • Products Overview
   • Company Market Share Analysis
   • Company Coverage Portfolio
   • Financial Analysis
   • Recent Developments
   • Merger and Acquisitions
   • SWOT Analysis.
2. Allergan plc
3. Novartis AG
4. Oxurion NV
5. Sirnaomics Inc.
6. Genentech
7. Alimera Sciences
8. Ampio Pharmaceuticals
9. BCN Peptides
10. Kowa Company, Ltd.

 

Conclusion

The Diabetic Retinopathy Market Size is poised for significant growth as rising diabetes prevalence, expanded screening, and therapeutic innovation align to curb vision loss globally. AI-driven diagnostics, teleophthalmology, and advanced noninvasive imaging will enable earlier, more accessible detection, while anti-VEGF agents, gene therapies, and sustained-release delivery systems offer improved outcomes and reduced treatment burden. Increased R&D investment, favorable reimbursement frameworks, and growing healthcare infrastructure in emerging markets will accelerate adoption. Collaboration among biopharma, device makers, and digital health providers will create integrated care pathways. Stakeholders prioritizing patient-centric, scalable, affordable, and sustainable solutions will lead market expansion over the coming decade globally.

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter